INTRODUCTION
Chriocarcinoma also known as trophoblastic tumour is a rare form of malignancy which occurs in the female genital tract and is commonly associated with pregnancy. It may develop after a normal pregnancy; however, it is usually associated with molar pregnancy, ectopic pregnancy, miscarriage, or abortion. 1 It has an incidence of about 1 in 30000 pregnancies. It should be considered when persistent bleeding follows any pregnancy event. 2 In most cases chriocarcinoma is associated with a positive pregnancy test even without pregnancy and with high levels of beta human chorionic gonadotrophic hormone (Bhcg).
CASE REPORT
29 years old para 3 women reported with symptoms of breathlessness, easy fatigability of three months duration and passing of dark tarry stools of 15 days duration. Her past history revealed a suction & evacuation done for molar pregnancy 3 years back with no follow up thereafter. The general physical examination revealed extreme pallor, pulse 110/min, BP 90/60 mm of Hg. In view of the medical history, clinical examination, laboratory and radiological investigations a final diagnosis of metastatic choriocarcinoma stage IV C (high risk with WHO prognostic score of >8) was arrived at.
Despite repeated blood transfusions her haemoglobin could not be raised to desired levels for the standard EMA-CO regimen (E-etoposide, M-methotrexate, Aactinomycin, C-cyclophospamide, O-vincristine). This was due to the actively bleeding gastrointestinal lesion.
To overcome this problem a innovative approach was attempted. She was started on single agent methotrexate (1.1 mg/kg) with the hope that the lesion would stop bleeding. The bleeding stopped within 48 hours as evidence by rise in haemoglobin levels with subsequent blood transfusions. Thereafter she was started on EMA-CO regimen (omitting methotrexate in first cycle). The BHCG fell to 188 IU/L before second cycle. Bhcg was undetected before third cycle of EMA-CO. She received total three cycles of chemotherapy as consolidation after Bhcg was undetectable making a total of five cycles. She was given a total of 20 packed red blood cells & 8 fresh frozen plasma over a period of 30 days. The post chemotherapy follow up has been for 5 years now and the patient is disease free.
DISCUSSION
Choriocarcinoma is an extremely malignant tumour, may be considered a carcinoma of the chorionic epithelium. Choriocarcinoma may arise from any type of pregnancy, including a normal term pregnancy and from homozygous or heterozygous complete mole. 3 Choriocarcinoma is suspected when there is abnormal uterine bleeding following an abortion or hydatidiform mole. This is one of the most frequent presentations of choriocarcinoma.
Not all patients have a demonstrable lesion in the uterus after an intrauterine gestation and at times, symptoms related to the metastasis are the first presentation. Metastasis of choriocarcinoma occurs most frequently in the lungs, brain and liver. The gastrointestinal tract can also be affected in less than 5% cases. There are few reports of metastatic choriocarcinoma affecting the gastrointestinal tract. It can present in the form of upper gastrointestinal bleeding, intussusception, ileal perforation or rectal bleeding. 4 Our case presented at a rare site in stomach with no evidence of disease in the uterus. A high index of suspicion in all childbearing age women can detect this rare malignancy with bizarre symptom presentation not related to genital tract as was in our case and a simple test of Bhcg in the workup of women with radiological evidence of systemic metastasis with unknown primary will help in saving these young women.
High risk choriocarcinoma, WHO prognostic score >7 is treated with EMA-CO regime with a cure rate between 67 and 85 percentage. 5, 6 These women should be managed in centers with expertise to deal with such cases as future fertility may also be an issue in young women. Our case despite being in poor general condition on presentation could be saved due to timely diagnosis and appropriate chemotherapy thus achieving complete remission.
The specific treatment of bleeding gastrointestinal lesion is controversial. The modalities of treatment suggested are surgery and angiographic embolization 7 without any survival benefit with these approaches. Our case presented with upper gastro intestinal bleed and the facilities of angiographic embolization did not exist at that time in the institution. So we tried an innovative approach to start with methotrexate as it less bone marrow suppressive. We could achieve the desired result of stopping upper GI bleed and thereafter give combination chemotherapy. We did not find this type of management approach on literature search. We recommend that in desperate situations an innovative individualized treatment may be life saving.
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